RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes

European Journal of Pharmacology

Volumn 652, Issue 1-3, 2011, Pages 157-163

  Singh, Shuchita ^a   Sethi, Sachin ^a   Khanna, Vivek ^a   Benjamin, Biju ^a   Kant, Rajiv ^a   Sattigeri, Jitendra ^a   Bansal, Vinay S ^a   Bhatnagar, Pradip Kumar ^a   Davis, Joseph Alex ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

Anti diabetic effect; Dipeptidyl peptidase IV; Glucagon like peptide 1; Oral glucose tolerance test; Type 2 diabetes mellitus

Indexed keywords

4 FLUORO 1 [N [ 3 [ (4 FLUOROPHENYL)CARBONYL] 3 AZABICYCLO[3.1.0]HEX 6 YL]GLYCYL]PYRROLIDINE 2 CARBONITRILE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPEPTIDYL PEPTIDASE IX; DIPEPTIDYL PEPTIDASE VIII; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PROLINE; PROTEINASE; RBX 0597; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME SPECIFICITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INSULIN; KINETICS; MALE; MICE; MICE, OBESE; RATS; RATS, WISTAR;

EID: 78650915884     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.06.001     Document Type: Article

References (31)

1. D.J. Augeri, J.A. Robl, D.A. Betebenner, D.R. Magnin, A. Khanna, J.G. Robertson, A. Wang, L.M. Simpkins, P. Taunk, Q. Huang, S.P. Han, B. Abboa-Offei, M. Cap, L. Xin, L. Tao, E. Tozzo, G.E. Welzel, D.M. Egan, J. Marcinkeviciene, S.Y. Chang, S.A. Biller, M.S. Kirby, R.A. Parker, and L.G. Hamann Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 48 2005 5025 5037
2. I. Brandt, J. Joossens, X. Chen, M.-B. Maes, S. Scharpe, I.D. Meester, and A.-M. Lambeir Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2 S)-{[3-hydroxyadamantan-1-yl)amino]acetyl}- pyrrolidine-2-carbonitrile) Biochem. Pharmacol. 70 2005 134 143
3. B.F. Burkey, P.K. Hoffman, U. Hassiepen, J. Trappe, M. Juedes, and J.E. Foley Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited Diabetes Obes. Metab. 10 2008 1057 1061
4. C.F. Deacon, M.A. Nauck, M. Toft-Nielsen, L. Pridal, B. Willms, and J.J. Holst Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy patients Diabetes 44 1995 1126 1131
5. C.F. Deacon, R.D. Carr, and J.J. Holst DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes Front. Biosci. 13 2008 1780 1794
6. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
7. R. Gupta, S.S. Walunj, R.K. Tokala, K.V. Parsa, S.K. Singh, and M. Pal Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 diabetes Curr. Drug Targets 10 2009 71 87
8. T.E. Hughes, M.D. Mone, M.E. Russell, S.C. Weldon, and E.B. Villhauer NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV Biochemistry 38 1999 11597 11603
9. D. Kim, L. Wang, M. Beconi, G.J. Eiermann, M.H. Fisher, H. He, G.J. Hickey, J.E. Kowalchick, B. Leiting, K. Lyons, F. Marsilio, M.E. McCann, R.A. Patel, A. Petrov, G. Scapin, S.B. Patel, R.S. Roy, J.K. Wu, M.J. Wyvratt, B.B. Zhang, L. Zhu, N.A. Thornberry, and A.E. Weber (2R)-4-Oxo-4-[3-(Trifluoromethyl) -5, 6-dihydro[1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-1-(2, 4, 5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 48 2005 141 151
10. Y.B. Kim, L.M. Kopcho, M.S. Kirby, L.G. Hamann, C.A. Weigelt, W.J. Metzler, and J. Marcinkeviciene Mechanism of Gly-pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118) Arch. Biochem. Biophys. 445 2006 9 18
11. A.M. Lambeir, C. Durinx, S. Scharpe, and I. De Meester Dipeptidyl peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV Crit. Rev. Clin. Lab. Sci. 40 2003 209 294
12. G.R. Lankas, B. Leiting, R.S. Roy, G.J. Eiermann, M.G. Beconi, T. Biftu, C.C. Chan, S. Edmondson, W.P. Feeney, H. He, D.E. Ippolito, D. Kim, K.A. Lyons, H.O. Ok, R.A. Patel, A.N. Petrov, K.A. Pryor, X. Qian, L. Reigle, A. Woods, J.K. Wu, D. Zaller, X. Zhang, L. Zhu, A.E. Weber, and N.A. Thornberry Dipeptidyl peptidase IV inhibition for the treatment of Type 2 diabetes. Potential importance of selectivity over dipeptidyl peptidases 8 and 9 Diabetes 54 2005 2988 2994
13. J.A. Lovshin, and D.J. Drucker Incretin-based therapies for type 2 diabetes mellitus Nat. Rev. Endocrinol. 5 2009 262 269
14. D. Marguet, L. Baggio, T. Kobayashi, A.M. Bernard, M. Pierres, P.F. Nielsen, U. Ribel, T. Watanabe, D.J. Drucker, and N. Wagtmann Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc. Natl Acad. Sci. 97 2000 6874 6879
15. C.H. McIntosh, H.U. Demuth, J.A. Pospisilik, and R. Pederson Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul. Pept. 128 2005 159 165
16. R. Mentlein Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP Best Pract. Res. Clin. Endocrinol. Metab. 23 2009 443 452
17. C. Morimoto, and S.F. Schlossman The structure and function of CD26 in the T-cell immune response Immunol. Rev. 161 1998 55 70
18. J.F. Morrison, and C.T. Walsh The behaviour and significance of slow-binding enzyme inhibitors Adv. Enzymol. 61 1988 201 216
19. E. Muscelli, A. Mari, A. Casolaro, S. Camastra, G. Seghieri, A. Gastaldelli, J.J. Holst, and E. Ferrannini Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients Diabetes 57 2008 1340 1348
20. T. Nagakura, N. Yasuda, K. Yamazaki, H. Ikutta, S. Yoshikawa, O. Asano, and I. Tanaka Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats Biochem. Biophys. Res. Commun. 284 2001 501 506
21. M.A. Nauck, N. Kleine, C. Orskov, J.J. Holst, B. Willms, and C. Creutzfeldt Normalization of fasting hyperglycemia by exogenous GLP-1 (7-36 amide) in type 2 diabetes patients Diabetologia 36 1993 741 744
22. R.A. Pederson, H.A. White, D. Schlenzig, R.P. Pauly, C.H. McIntosh, and H.U. Demuth Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide Diabetes 47 1998 1253 1258
23. Sattigeri, J.A., Andappan, M.M.S., Kishore, K., Sethi, S., Kandalkar, S.R., Pal, C.K., Mahajan, D.C., Ahmed, S., Parkale, S.S., Srinivasan, T., Sharma, L., Bansal, V.S., Chugh, A., Davis, J.A., 2007. Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-IV inhibitors. Patent No. WO 2007/029086.
24. M. Stumvoll, B.J. Goldstein, and T.W. Van Haeften Type 2 diabetes: principles of pathogenesis and therapy Lancet 365 2005 1333 1346
25. K. Takasaki, M. Iwase, T. Nakajima, K. Ueno, Y. Nomoto, S. Nakanishi, and K. Higo K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent Eur. J. Pharmacol. 486 2004 335 342
26. L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, and M. Mark (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl- quinazolin-2-ylmethyl)-3, 7-dihydro-purine-2, 6-dione (Bl 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors J. Pharmacol. Exp. Ther. 325 2008 175 182
27. TM (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Curr. Top. Med. Chem. 7 2007 557 568
28. J.I. Venäläinen, R.O. Juvonen, M.M. Forsberg, A. Garcia-Horsman, A. Poso, E.A.A. Wallen, J. Gynther, and P.T. Männistö Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819 Biochem. Pharmacol. 64 2002 463 471
29. E.B. Villhauer, J.A. Brinkman, G.B. Naderi, B.F. Burkey, B.E. Dunning, K. Prasad, B.L. Mangold, M.E. Russell, and T.E. Hughes 1-[[(3-Hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J. Med. Chem. 46 2003 2774 2789
30. T. Vilsbøll, T. Krarup, C.F. Deacon, S. Madsbad, and J.J. Holst Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetes patients Diabetes 50 2001 609 613
31. J.-J. Wu, H.-K. Tang, T.-K. Yeh, C.-M. Chen, H.-S. Shy, Y.-R. Chu, C.-H. Chien, T.-Y. Tsai, Y.-C. Huang, Y.-L. Huang, C.-H. Huang, H.-Y. Tseng, W.-T. Jiaang, Y.-S. Chao, and X. Chen Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor Biochem. Pharmacol. 78 2009 203 210